Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Kenneth Galbraith
|
| gptkbp:collaboratedWith |
gptkb:Eli_Lilly
gptkb:Janssen_Biotech gptkb:Merck gptkb:Daiichi_Sankyo |
| gptkbp:focusesOn |
oncology
protein therapeutics antibody therapeutics |
| gptkbp:foundedBy |
gptkb:Ali_Tehrani
|
| gptkbp:foundedYear |
2003
|
| gptkbp:headquartersLocation |
gptkb:Vancouver,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zymeworks
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
gptkb:Toronto_Stock_Exchange |
| gptkbp:numberOfEmployees |
over 300
|
| gptkbp:platform |
AlbuCORE
Azymetric EFECT |
| gptkbp:productPipelineIncludes |
ZW49
zanidatamab |
| gptkbp:subsidiary |
Zymeworks Biopharmaceuticals Inc.
|
| gptkbp:tradedOn |
NASDAQ: ZYME
|
| gptkbp:website |
https://www.zymeworks.com/
|
| gptkbp:bfsParent |
gptkb:Zymeworks_(regional_office)
gptkb:Baker_Bros._Advisors |
| gptkbp:bfsLayer |
7
|